Lupin Entered into an Exclusive License Agreement with I’rom for Denosumab Biosimilar in Japan
- Lupin will receive multiple milestones fees payments & I’rom will be responsible to conduct clinical trials, registering, distributing, and marketing biosimilar Denosumab in Japan under collaboration with Lupin
- I’rom will exclusively commercialize the product in Japan, upon the successful completion of the clinical trial and receipt of marketing authorization from PMDA
- Denosumab is currently available under two brands i.e., Pralia and Ranmark & is indicated for the treatment of postmenopausal women with osteoporosis who are at a high risk of fracture and the prevention of skeletal-related events in patients with solid tumor bone metastases
Ref: Lupin | Image: Lupin
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.